~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway for AMT-130 in Huntington’s disease ~ ~ Presented positive interim data from Phase I/II trial of AMT-130 demonstrating slowing of Huntington’s disease progression and reductions in key biomarker of neurodegeneration ~ ~ Initiated patient dosing in new Phase I/II studies of AMT-162 in SOD1-ALS and AMT-191 in Fabry disease; First patient enrolled in observa ...

UniQure (QURE) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.24. This compares to loss of $1.44 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 6.45%. A quarter ago, it was expected that this human gene therapy company would post a loss of $1.31 per share when it actually produced a loss of $1.36, delivering a surprise of -3.82%. Over the last four quarters, the company ...

Exhibit 99.1 uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update ~ Announced RMAT designation for AMT-130 in Huntington's disease and positive interim Phase I/II data demonstrating the slowing of disease progression and reductions in a key biomarker of neurodegeneration; Meeting with FDA expected in the second half of 2024 to discuss potential for expedited clinical development ~ ~ Initiated patient screening for three additional Phase I/II studies in mesial temporal lobe epi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-36294 uniQure N.V. (Exact name of Registrant as specified in its charter) The Netherlands (Stat ...

~ Announced RMAT designation for AMT-130 in Huntington's disease and positive interim Phase I/II data demonstrating the slowing of disease progression and reductions in a key biomarker of neurodegeneration; Meeting with FDA expected in the second half of 2024 to discuss potential for expedited clinical development ~ ~ Initiated patient screening for three additional Phase I/II studies in mesial temporal lobe epilepsy, SOD1 ALS, and Fabry disease ~ ~ Today, announced an organizational restructuring intended ...

~ Announced RMAT designation for AMT-130 in Huntington's disease and positive interim Phase I/II data demonstrating the slowing of disease progression and reductions in a key biomarker of neurodegeneration; Meeting with FDA expected in the second half of 2024 to discuss potential for expedited clinical development ~ ~ Initiated patient screening for three additional Phase I/II studies in mesial temporal lobe epilepsy, SOD1 ALS, and Fabry disease ~ ~ Today, announced an organizational restructuring intended ...

LEXINGTON, Mass. and AMSTERDAM, July 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of the sale of its global manufacturing facility in Lexington, Massachusetts to Genezen, a leading contract development and manufacturing organization specializing in the supply of retroviral vectors, lentiviral vectors, and adeno-associated virus (AAV) technologies. With the transa ...

~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~ ~ Immediate reduction in cash burn, projected to save $40 million annually ~ LEXINGTON, Mass. and AMSTERDAM, July 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of the sale of its global manufacturing facility in Lexington, Mas ...

In this April 6, 2016, photo, Ed Izenstark and his son Chase, 4, pose in St. Charles, Ill. Izenstark ... [+] inherited a genetic predisposition to Huntington's disease from his birth father, but he only learned of his susceptibility to the fatal nerve disorder after requesting information about his adoption from a state agency last December. Illinois state Rep. Sara Feigenholtz, D-Chicago, wants to make adoption records more transparent to help thousands of people across the state access more details about ...

The average comprises 11 short-term price targets ranging from a low of $6 to a high of $32, with a standard deviation of $8.63. While the lowest estimate indicates a decline of 10% from the current price level, the most optimistic estimate points to a 379.8% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. However, an impressive consensus price targ ...